Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Figure 6

cost-effectiveness plot, cost per QALY. QALY: quality adjusted life year; CE: cost-effectiveness

The majority of simulations from the PSA are in the top right quadrant demonstrating the confidence limits that surround the base case scenario. Threshold values at € 30000, € 60000 and € 90000 have been added to show the number of iterations that fall within each ICER threshold.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us